[1] Dutta R, Mahato RI . Recent advances in hepatocellular carcinoma therapy. Pharmacol Therapeut, 2017, 173:106-117.
[2] 邓兰, 蒋益兰, 江摩, 等. TACE联合中药治疗原发性肝癌患者初步临床研究. 实用肝脏病杂志, 2017, 20:242-243.
[3] 陈宵瑜, 杨长青. 肝纤维化发生机制研究新进展. 实用肝脏病杂志, 2016, 19:121-124.
[4] 倪卓然, 谢坤, 赵红川, 等. 肝细胞癌组织中Shh、Gli1、Snail、E-cadherin表达的临床研究. 安徽医科大学学报, 2016, 51:536-541.
[5] 万磊, 陈青松, 周壮, 等. 丹酚酸B通过调控SIRT1/NF-κB/p53通路减轻缺氧/复氧诱导的大鼠肝细胞损伤. 中国药理学通报, 2018,33:121-124.
[6] 黄风玲, 杨颖, 张瑞丽, 等. 肝细胞癌组织中高尔基体蛋白73和转化生长因子β1及Smad2的表达水平及其意义. 中国全科医学, 2016, 19:3191-3195.
[7] Li Q , Liu G, Yuan H , et al. Mucin1 shifts Smad3 signaling from the tumor-suppressive pSmad3C/p21 WAF1, pathway to the oncogenic pSmad3L/c-Myc pathway by activating JNK in human hepatocellular carcinoma cells. ONCOTARGET, 2015, 6:4253-4265.
[8] Liu R, Tang C, Shen A , et al. IL-37 suppresses hepatocellular carcinoma growth by converting pSmad3 signaling from JNK/pSmad3L/c-Myc oncogenic signaling to pSmad3C/P21 tumor-suppressive signaling. ONCOTARGET, 2016, 51:8507-8510. |
